Stifel Downgrades Mirati Therapeutics (MRTX) to Hold

Stifel analyst Ben Burnett downgraded Mirati Therapeutics (NASDAQ: MRTX) from Buy to Hold with a price target of $59.00 (from $83.00).

For an analyst ratings summary and ratings history on Mirati Therapeutics click here. For more ratings news on Mirati Therapeutics click here.

Shares of Mirati Therapeutics closed at $56.02 yesterday.

You May Also Be Interested In

• William Blair Downgrades Enovix Corporation (ENVX) to Market Perform
• Deutsche Bank Downgrades Workday (WDAY) to Hold
• Central Retail Corp PCL (CRC:TB) PT Lowered to THB9,000 at Macquarie